Kura Oncology, Inc. (KURA) vs Latigo Biotherapeutics Inc. (LTGO)

A side-by-side comparison of Kura Oncology, Inc. and Latigo Biotherapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

KURA

Kura Oncology, Inc.

$951M

$10.71HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT

LTGO

Latigo Biotherapeutics Inc.

$1.00B

$16.67HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT

Total return — KURA vs LTGO

growth of $100 · dividends reinvested · last 1y

KURA +15.4% (+15.4%/yr)LTGO -7.6% (-7.6%/yr)KURA compounded faster over this window

KURA LTGO

Metrics side by side

Total return (annualized)

Metric	KURA	LTGO
Total return (1Y)	10.92%	N/A
Total return CAGR (3Y)	6.59%	N/A
Total return CAGR (5Y)	-10.73%	N/A
Total return CAGR (10Y)	5.98%	N/A

LTGO is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full KURA analysis Full LTGO analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.